文献速递血栓与止血

PF-06741086(抗组织因子途径抑制物单克隆抗体)在健康志愿者中的安全性、耐受性、药代动力学和药效学首次人体研究

A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
PubMed 文献 · J Thromb Haemost · 2018-07-20

该研究为随机、双盲、申办方开放、安慰剂对照的单次静脉或皮下剂量递增研究,纳入41名男性健康志愿者,其中32名接受PF-06741086(皮下30 mg至静脉440 mg)给药。所有剂量安全且耐受良好,不良事件为轻至中度,无严重不良事件,无输注/注射部位反应,未达到剂量递增停止标准;血浆暴露随剂量增加呈超比例增加,并通过总TFPI、稀释凝血酶原时间、D-二聚体、凝血酶原片段1+2和凝血酶生成试验参数证实了凝血药理学作用。

要点

  • PF-06741086单次给药(皮下30 mg至静脉440 mg)在健康男性中安全且耐受良好。
  • 不良事件为轻至中度,实验室异常为一过性,无严重不良事件,无输注/注射部位反应。
  • 血浆暴露随剂量增加呈超比例增加,凝血药理学作用通过总TFPI等参数证实。

核心结论

  • 单次多剂量水平的PF-06741086在健康成年男性人群中安全且耐受良好,其安全性、药代动力学和药效学数据支持在血友病患者中开展多次给药研究。

研究设计与样本

  • 随机、双盲、申办方开放、安慰剂对照的单次静脉或皮下剂量递增研究,共招募41名男性健康志愿者,其中32名接受PF-06741086给药,剂量从皮下30 mg至静脉440 mg。

主要发现

  • 所有剂量均安全且耐受良好,治疗中出现的不良事件为轻至中度,实验室异常为一过性,无严重不良事件,无输注/注射部位反应,未达到剂量递增停止标准。
  • 相同给药途径下,PF-06741086的血浆暴露随剂量增加呈超比例增加。
  • 通过总TFPI、稀释凝血酶原时间、D-二聚体、凝血酶原片段1+2和凝血酶生成试验参数证实了凝血药理学作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Tissue factor pathway inhibitor (TFPI) is an antagonist of FXa and the TF-FVIIa complex. PF-06741086 is an IgG1 monoclonal antibody that targets the Kunitz-2 domain of TFPI. Single doses of PF-06741086 were evaluated in a phase 1 study in healthy volunteers. Data from this study support further investigation of PF-06741086 in individuals with hemophilia. SUMMARY: Background Tissue factor pathway inhibitor (TFPI) is a protease inhibitor of the tissue factor-activated factor VII complex and activated FX. PF-06741086 is a mAb that targets TFPI to increase clotting activity. Objectives This study was a randomized, double-blind, sponsor-open, placebo-controlled, single intravenous or subcutaneous dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086. Patients/Methods Volunteers who provided written informed consent were assigned to cohorts with escalating dose levels. Safety endpoints included treatment-emergent adverse events (TEAEs), infusion/injection site reactions, vital signs, electrocardiogram, and coagulation and hematology laboratory parameters. Pharmacokinetic (PK) and pharmacodynamic (PD) endpoints included exposures of PF-06741086 in plasma and measures of PF-06741086 pharmacology, respectively. Results Forty-one male volunteers were recruited overall. Thirty-two were dosed with PF-06741086 from 30 mg subcutaneously to 440 mg intravenously. All doses were safe and well tolerated. TEAEs were mild or moderate in severity, laboratory abnormalities were transient, there were no serious adverse events, there were no infusion/injection site reactions, and no dose escalation stopping criteria were met. Plasma exposures of PF-06741086 increased greater than proportionally with dose under the same dosing route. Coagulation pharmacology was demonstrated via total TFPI, dilute prothrombin time, D-dimer, prothrombin fragment 1 + 2 and thrombin generation assay parameters. Conclusions Single doses of PF-06741086 at multiple dose levels were safe and well tolerated in a healthy adult male population. The safety, PK and PD data from this study support progression to a multiple-dose study in hemophilic patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Cardinal M, Kantaridis C, Zhu T, et al. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers. J Thromb Haemost. 2018. PMID: 29908043. doi:10.1111/jth.14207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。